A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Scientific breakthroughs, operational innovation, and cultural shifts are driving tomorrow’s medicines.

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be ...

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

Leveraging computerized maintenance management systems software can enhance efficiency, improve quality control, ensure ...

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics ...

Pharmaceutical Technology® spoke with Martin Meeson, CEO of Axplora, about the role contract development and manufacturing ...

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) ...

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only ...

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, ...

The concerns of industry experts expressed at INTERPHEX in April 2025 are still pertinent in an uncertain global political ...